Trial Profile

Safety and Anti-HIV Activity of Autologous CD4+ and CD8+ T Cells Transduced With a Lentiviral Vector Encoding Bi-specific Anti-gp120 CAR Molecules (LVgp120duoCAR-T) in Anti-retroviral Drug-treated HIV-1 Infection

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-HIV duoCAR-T cell therapy-Lentigen Technology/University of Pittsburgh (Primary) ; Cyclophosphamide
Indications HIV-1 infections
Focus Adverse reactions; First in man; Therapeutic Use

17 Jun 2024 Planned End Date changed from 31 Dec 2027 to 31 Dec 2028.
17 Jun 2024 Planned primary completion date changed from 31 Dec 2026 to 31 Dec 2027.
26 May 2023 Planned End Date changed from 31 Dec 2025 to 31 Dec 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com